Want to join the conversation?
Biopharmaceutical company $AMGN said that in Phase 2 confirmatory multicenter single-arm trial (BLAST) for adult patients having B-cell precursor acute lymphoblastic leukemia with minimal residual disease (MRD), i.e. cancer cells from bone marrow, who received BLINCYTO monotherapy showed clinically relapse-free survival (RFS).
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?